1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Septicaemia - Pipeline Review, H2 2014

Septicaemia - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 34 pages

Septicaemia - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Septicaemia - Pipeline Review, H2 2014’, provides an overview of the Septicaemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Septicaemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Septicaemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Septicaemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Septicaemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Septicaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Septicaemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Septicaemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Septicaemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Septicaemia - Pipeline Review, H2 2014
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Septicaemia Overview 6
Therapeutics Development 7
Pipeline Products for Septicaemia - Overview 7
Pipeline Products for Septicaemia - Comparative Analysis 8
Septicaemia - Therapeutics under Development by Companies 9
Septicaemia - Therapeutics under Investigation by Universities/Institutes 10
Septicaemia - Pipeline Products Glance 11
Early Stage Products 11
Septicaemia - Products under Development by Companies 12
Septicaemia - Products under Investigation by Universities/Institutes 13
Septicaemia - Companies Involved in Therapeutics Development 14
Cubist Pharmaceuticals, Inc. 14
Diomune S.L 15
Humabs BioMed SA 16
Sinovac Biotech Ltd. 17
Septicaemia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Molecule Type 23
Drug Profiles 25
Monoclonal Antibody for Staphylococcus Aureus Infections - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Oncocin Analogues for Septicaemia - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
pneumococcal polysaccharide (23-valent) vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Small Molecules for Human Septicaemia - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Small Molecules to Antagonize TLR-4 for Septicemia and Septic Shock - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Septicaemia - Recent Pipeline Updates 31
Septicaemia - Discontinued Products 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables

Number of Products under Development for Septicaemia, H2 2014 7
Number of Products under Development for Septicaemia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Septicaemia - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 14
Septicaemia - Pipeline by Diomune S.L, H2 2014 15
Septicaemia - Pipeline by Humabs BioMed SA, H2 2014 16
Septicaemia - Pipeline by Sinovac Biotech Ltd., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Septicaemia Therapeutics - Recent Pipeline Updates, H2 2014 31
Septicaemia - Discontinued Products, H2 2014 32

List of Figures

Number of Products under Development for Septicaemia, H2 2014 7
Number of Products under Development for Septicaemia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Top 10 Targets, H2 2014 19
Number of Products by Stage and Top 10 Targets, H2 2014 19
Number of Products by Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Top 10 Molecule Types, H2 2014 23
Number of Products by Stage and Top 10 Molecule Types, H2 2014 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.